Rotavirus vaccines: current prospects and future challenges

Lancet

Volumn 368, Issue 9532, 2006, Pages 323-332

  Glass, Roger I ^a   Parashar, Umesh D ^a   Bresee, Joseph S ^a   Turcios, Reina ^a   Fischer, Thea K ^a   Widdowson, Marc Alain ^a   Jiang, Baoming ^a   Gentsch, Jon R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE ROTAVIRUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RIX 4414; ROTAVIRUS VACCINE; SIMIAN ROTAVIRUS VACCINE; VP 7; WC 3;

CHILD DEATH; CHILD HEALTH; CHILD HEALTH CARE; CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; IMMUNITY; IMMUNIZATION; INTUSSUSCEPTION; LABORATORY TEST; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; SURVIVAL RATE; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

EID: 33745987658     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68815-6     Document Type: Review

References (110)

1. Kosek M., Bern C., and Guerrant R. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 81 (2003) 197-204
2. Black R., Morris S., and Bryce J. Where and why are 10 million children dying every year?. Lancet 361 (2003) 2226-2234
3. UN. Millenium Development Goals Report (2005), UN, New York. http://www.un.org/millenniumgoals/ (accessed Dec 10, 2005)
4. Bresee J., Fang Z., Wang B., et al. First report from the Asian Rotavirus Surveillance Network. Emerg Infect Dis 10 (2004) 988-995
5. Cunliffe N., Kilgore P., Bresee J., Hart C., and Glass R. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull World Health Organ 76 (1998) 525-537
6. Kane E., Turcios R., Arvay M., Garcia S., Bresee J., and Glass R. The epidemiology of rotavirus diarrhea in Latin America. Anticipating rotavirus vaccines. Rev Panam Salud Publica 16 (2004) 371-377
7. Parashar U., Hummelman E., Bresee J., Miller M., and Glass R. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 9 (2003) 565-572
8. Parashar U., Gibson C., Bresee J., and Glass R. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12 (2005) 304-306
9. Clark H., Offit P., Glass R., and Ward R. Rotavirus vaccines. In: Plotkin S., and Orenstein W. (Eds). Vaccines. 4th edn. (2004), Saunders-Elsevier, Philadelphia 1327-1345
10. Glass R., Bresee J., Turcios R., Fischer T., Parashar U., and Steele A. Rotavirus vaccines: targeting the developing world. J Infect Dis 192 suppl 1 (2005) S160-S166
11. Cook S., Glass R., LeBaron C., and Ho M.-S. Global seasonality of rotavirus infections. Bull World Health Organ 68 (1990) 171-177
12. Jain V., Parashar U., Glass R., and Bhan M. Epidemiology of rotavirus in India. Indian J Pediatr 68 (2001) 855-862
13. Villa S., Guiscafre H., Martinez H., Munoz O., and Gutierrez G. Seasonal diarrrhoeal mortality among Mexican children. Bull World Health Organ 77 (1999) 375-380
14. Parashar U., Bresee J., and Glass R. The global burden of diarrhoeal disease in children. Bull World Health Organ 81 (2003) 236
15. Lynch M., Shieh W., Tatti K., et al. The pathology of rotavirus-associated deaths, using new molecular diagnostics. Clin Infect Dis 37 (2003) 1327-1333
16. Morrison C., Gilson T., and Nuovo G. Histologic distribution of fatal rotaviral infection: an immunohistochemical and reverse transcriptase in situ polymerase chain reaction analysis. Hum Pathol 32 (2001) 216-221
17. Carlson J., Middleton P., Szymanski M., Huber J., and Petric M. Fatal rotavirus gastroenteritis: an analysis of 21 cases. Am J Dis Child 132 (1978) 477-479
18. Kapikian A., Hoshino Y., and Chanock R. Rotaviruses. In: Knipe D., and Howley P. (Eds). Fields virology. 4th edn. (2001), Lippincott-Raven, Philadelphia 1787-1833
19. Estes M. Rotaviruses and their replication. In: Knipe D., and Howley P. (Eds). Fields virology. 4th edn. (2001), Lippincott-Raven, Philadelphia 1747-1787
20. Ball J., Tian P., Zeng C.-Y., Morris A., and Estes M. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 272 (1996) 101-104
21. Blutt S., Kirkwood C., Parreno V., et al. Rotavirus antigenaemia and viraemia: a common event?. Lancet 362 (2003) 1445-1449
22. Fischer T., Ashley D., Kerin T., et al. Rotavirus antigenemia in patients with acute gastroenteritis. J Infect Dis 192 (2005) 913-919
23. Gilger M., Matson D., Conner M., Rosenblatt H., Finegold M., and Estes M. Extraintestinal rotavirus infections in children with immunodeficiency. J Pediatr 120 (1992) 912-917
24. Lynch M., Lee B., Azimi P., et al. Rotavirus and central nervous system symptoms: cause or contaminant? Case reports and review. Clin Infect Dis 33 (2001) 932-938
25. Pang X.-L., Joensuu J., and Vesikari T. Detection of rotavirus RNA in cerebrospinal fluid in a case of rotavirus gastroenteritis with febrile seizures. Pediatr Infect Dis J 15 (1996) 543-545
26. Ushijima H., Xin K., Nishimura S., Morikawa S., and Abe T. Detection and sequencing of rotavirus VP7 gene from human materials (stools, sera, cerbrospinal fluids, and throat swabs) by reverse transcription and PCR. J Clin Microbiol 32 (1994) 2893-2897
27. Cicirello H., Das B., Gupta A., et al. High prevalence of rotavirus infection among neonates born at hospitals in Delhi, India: predisposition of newborns for infection with unusual rotavirus. Pediatr Infect Dis J 13 (1994) 720-724
28. Kilgore P., Unicomb L., Gentsch J., Albert M., McElroy C., and Glass R. Neonatal rotavirus infection in Bangladesh: strain characterization and risk factors for nosocomial infection. Pediatr Infect Dis J 15 (1996) 672-677
29. Omoigberale A., and Abiodun P. Nosocomial rotavirus infection in newborns. East Afr Med J 72 (1995) 220-221
30. Bishop R., Barnes G., Cipriani E., and Lund J. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 309 (1983) 72-76
31. Velazquez F., Calva J., Ruiz-Palacios G., et al. Cohort study of rotavirus serotype patterns in symptomatic and asymptomatic infections in Mexican children. Pediatr Infect Dis J 12 (1993) 54-61
32. Gentsch J., Laird A., Bielfelt B., et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 192 suppl 1 (2005) S146-S159
33. Cunliffe N., Bresee J., Gentsch J., and Glass R. The expanding diversity of rotaviruses. Lancet 359 (2002) 640-642
34. Desselberger U., Iturriza-Gomara M., and Gray J. Rotavirus epidemiology and surveillance. Novartis Found Symp 238 (2001) 125-152
35. Koshimura Y., Nakagomi T., and Nakagomi O. The relative frequencies of G serotypes of rotaviruses recovered from hospitalized children with diarrhea: a 10-year survey (1987-1996) in Japan with a review of globally collected data. Microbiol Immunol 44 (2000) 499-510
36. Santos N., and Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15 (2005) 29-56
37. Iturriza-Gomara M., Green J., Brown D., Tamsay M., Desselberger U., and Gray J. Molecular epidemiology of human group A rotavirus infections in the United Kingdom between 1995 and 1998. J Clin Microbiol 38 (2000) 4394-4401
38. Ramachandran M., Das B., Vij A., et al. Unusual diversity of human rotavirus G and P genotypes in India. J Clin Microbiol 34 (1996) 436-439
39. st century. J Infect Dis 192 suppl 1 (2005) S120-S126
40. Greenberg H., Kalica A., Wyatt R., Jones R., Kapikian A., and Chanock R. Rescue of noncultivatable human rotavirus by gene reassortment during mixed infection with ts mutants of a cultivatable bovine reassortant. Proc Natl Acad Sci USA 78 (1981) 420-424
41. Kapikian A., Hoshino Y., Chanock R., and Perez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 174 suppl 1 (1996) S65-S72
42. Clark H., Offit P., Ellis R., et al. WC3 reassortant vaccines in children. Arch Virol 12 suppl (1996) 187-198
43. Clements-Mann M., Makhene M., Mrukowicz J., et al. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3, or 4 in adults, children and infants. Vaccine 17 (1999) 2715-2725
44. WHO. Report of the meeting on future directions for rotavirus vaccine research in developing countries (2000), World Health Organization, Geneva 1-56
45. In: Gray J., and Desselberger U. (Eds). Rotavirus, methods and protocols (2000), Humana Press, Ottowa
46. Bhan M., Lew J., Sazawal S., Das B., Gentsch J., and Glass R. Protection conferred by neonatal rotavirus infection against subsequent diarrhea. J Infect Dis 168 (1993) 282-287
47. Velazquez F., Matson D., Calva J., et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 335 (1996) 1022-1028
48. Grimwood K., Lund J., Coulson B., Hudson I., Bishop R., and Baenes G. Comparison of serum and mucosal antibody responses following severe acute rotavirus gastroenteritis in young children. J Clin Microbiol 26 (1988) 732-738
49. Jiang B., Gentsch J., and Glass R. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin Infect Dis 34 (2002) 1351-1361
50. Ward R., and Bernstein D. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. Vaccine 13 (1995) 1226-1232
51. Westerman L., McClure H., Jiang B., Almond J., and Glass R. Serum IgG mediates mucosal immunity against rotavirus infection. Proc Natl Acad Sci USA 102 (2005) 7268-7273
52. Institute of Medicine. The prospects of immunizing against rotavirus. New vaccine development: diseases of importance in developing countries (1986), National Academy Press, Washington, DC 308-318
53. Bresee J., Glass R., Ivanoff B., and Gentsch J. Current status and future priorities for rotavirus vaccine development, evaluation, and implementation in developing countries. Vaccine 17 (1999) 2207-2222
54. Vesikari T., Isolauri E., and D'Hondt E. Protection of infants against rotavirus diarrhea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1 (1984) 977-981
55. Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. MMWR Morb Mortal Wkly Rep 48 (1999) 1-20
56. Perez-Schael I., Guntinas M., Perez M., et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 337 (1997) 1181-1209
57. Bernstein D., Glass R., Rodgers G., Davidson B., and Sack D. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 273 (1995) 1191-1196
58. Rennels M., Glass R., Dennehy P., Bernstein D., Pichichero M., and Zito E. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the national multicenter trial. Pediatrics 97 (1996) 7-13
59. Smith P., Schwartz B., Mokdad A., Bloch A., McCauley M., and Murphy T. The first oral rotavirus vaccine, 1998-1999: estimates of uptake from the National Immunization Survey. Public Health Rep 118 (2003) 134-143
60. Peter G., and Myers M. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 110 (2002) e67
61. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine, United States, 1998-1999. MMWR Morb Mortal Wkly Rep 48 (1999) 577-581
62. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 48 (1999) 1007
63. Simonsen L., Morens D., Elixhauser A., Gerber M., Van Raden M., and Blackwelder W. Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception. Lancet 358 (2001) 1224-1227
64. Chang H., Smith P., Ackelsberg J., Morse D., and Glass R. Intussusception, rotavirus diarrhea, and rotavirus vaccine use among children in New York state. Pediatrics 108 (2001) 54-60
65. Murphy B., Morens D., Simonsen L., Chanock R., La Montagne J., and Kapikian A. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 187 (2003) 1301-1308
66. Murphy T., Gargiullo P., Massoudi M., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344 (2001) 564-572
67. Simonsen L., Viboud C., Elixhauser A., Taylor R., and Kapikian A. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 192 suppl 1 (2005) S36-S43
68. Parashar U., Holman R., Cummings K., et al. Trends in intussusception-associated hospitalizations and deaths among US infants. Pediatrics 106 (2000) 1413-1421
69. Heaton P., Goveia M., Miller J., Offit P., and Clark H. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 192 suppl 1 (2005) S17-S21
70. Phua K., Quak S., Lee B., et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled Phase 2 trial involving 2464 Singaporean infants. J Infect Dis 192 suppl 1 (2005) S6-S16
71. De Vos B., Vesikari T., Linhares A., et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J 23 10 suppl (2004) S179-S182
72. Bernstein D., Sack D., Rothstein E., et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 354 (1999) 287-290
73. Vesikari T., Karvonen A., Korhonen T., et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 22 (2004) 2836-2842
74. Vesikari T., Karvonen A., Puustinen L., et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 23 (2004) 937-943
75. Linhares A., Ruiz-Palacios G., Guerrero M., et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine (2005). published online Aug 9. doi:10.1016/j.vaccine.2005.07.027
76. Salinas B., Perez Shael I., Linhares A., et al. Evaluation of safety, immunogenicity and efficacy of an attentuated rotavirus vaccine, RIX 4414: a randomized, placebo controlled trial in Latin American infants. Pediatr Infect Dis J 24 (2005) 807-816
77. Ruiz-Palacios G., Perez-Schael I., Velazquez F., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 (2006) 11-22
78. Macias M, Lopez P, Velazquez FR, et al. The rotavirus vaccine RIX 4414 (Rotarix) is not associated with intussusception in one year old infants. Interscience Conference on Antimicrobial Agents and Chemotherapy, Dec 16-19, 2005. Washington DC, Poster No. G-841.
79. Clark H., Offit P., Ellis R., et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 174 suppl 1 (1996) S73-S80
80. Clark H., Borian F., Bell L., and Plotkin S. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 158 (1988) 570-587
81. Bernstein D., Smith V., Sander D., Pax K., Schiff G., and Ward R. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 162 (1990) 1055-1062
82. Georges-Courbot M., Monges J., Siopathis M., et al. Evaluation of the effiacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 142 (1991) 405-411
83. Clark H., Burke C., Volkin D., et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatric Infect Dis J 22 (2003) 914-920
84. Vesikari T., Matson D., Dennehy P., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 (2006) 23-33
85. Das B., Gentsch J., Hoshino Y., et al. Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E. Virology 197 (1993) 99-107
86. Glass R., Bhan M., Ray P., et al. Development of candidate rotavirus vaccines derived from neonatal strains in India. J Infect Dis 192 suppl 1 (2005) S30-S35
87. Vethanayagam R., Ananda Babu M., Nagalaxmi K., et al. Possible role of neonatal infection with the asymptomatic reassortant rotavirus (RV) strain I321 in the decrease in hospital admissions for RV diarrhea, Bangalore, India, 1988-1999. J Infect Dis 189 (2004) 2282-2289
88. Barnes G., Lund J., Adams L., et al. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. J Paediatr Child Health 33 (1997) 300-304
89. Barnes G., Lund J., Mitchell S., et al. Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine 20 (2002) 2950-2956
90. Kapikian A., Simonsen L., Vesikari T., et al. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis 192 suppl 1 (2005) S22-S29
91. Ciarlet M., Crawford S., Barone C., et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol 72 (1998) 9233-9246
92. Jiang B., Estes M., Barone C., et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 17 (1999) 1005-1013
93. Estes M., Ball J., Crawford S., et al. Virus-like particle vaccines for mucosal immunization. In: Paul P., Francis D., and Benfield D. (Eds). Mechanisms in the pathogenesis of enteric diseases (1997), Plenum Press, New York 387-395
94. Choi A., Basu M., McNeal M., Bean J., Clements J., and Ward R. Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice. Protein Expr Purif 38 (2004) 205-216
95. Herrmann J., Chen S., Fynan E., et al. Protection against rotavirus infections by DNA vaccination. J Infect Dis 174 suppl (1996) S93-S97
96. Coffin S., Klinek M., and Offit P. Induction of virus-specific antibody production by lamina propria lymphocytes following intramuscular inoculation with rotavirus. J Infect Dis 172 (1995) 874-878
97. Conner M., Crawford S., Barone C., and Estes M. Rotavirus vaccine administered parenterally induces protective immunity. J Virol 67 (1993) 6633-6641
98. De Mol P., Zissis G., Butlzler J., Mutwewingabo A., and Andre F. Failure of live, attenuated oral rotavirus vaccine. Lancet 2 (1980) 108
99. Hanlon P., Marsh V., Jobe O., et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1 (1987) 1342-1345
100. Lanata C., Midthun K., Black R., et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 174 suppl 1 (1996) 268-275
101. Lanata C., Black R., Flores J., et al. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. Vaccine 14 (1996) 237-243
102. Lanata C., Black R., del Aguila R., et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 159 (1989) 452-459
103. Linhares A., Gabbay Y., Mascarenhas J., et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine Belem, Brazil. Bull World Health Organ 74 (1996) 491-500
104. Glass R. Commentary: reanalysis of the results of two rotavirus vaccine trials: an appraisal of the reappraisal. Ped Infect Dis J 18 (1999) 1006-1007
105. UK Government. International Finance Facility Proposal (2004-2004), United Kindgom Government, London. http://www.hm-treasury.gov.uk/media/D64/78/IFF_proposal_doc_080404.pdf (accessed Dec 14, 2005)
106. Clemens J., and Jodar L. Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Nat Med 11 4 suppl (2005) S12-S15
107. Rotavirus Vaccine Program. http://www.rotavirusvaccine.org/ Seattle: Rotavirus Vaccine Program (accessed Dec 14, 2005)
108. Steele A., Peenze I., Beer M., et al. Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa. Vaccine 21 (2003) 354-360
109. WHO. Generic protocols (i) hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children and (ii) a community based survey on utilization of health care services for gastroenteritis in children (2002), World Health Organization, Geneva 1-67. http://www.who.int/vaccines-documents (accessed Dec 15, 2005)
110. Bresee J., Hummelman E., Nelson E., and Glass R. Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines. J Infect Dis 192 suppl 1 (2005) S1-S5